Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + cyclophosphamide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Canadian Myeloma Research Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
DCd is a combination chemotherapy and immunotherapy regimen consisting of daratumumab, cyclophosphamide, and dexamethasone. It is primarily used for the treatment of patients with relapsed and refractory multiple myeloma (RRMM), particularly those who are lenalidomide-refractory. Daratumumab is a human IgG1 monoclonal antibody that targets CD38, a glycoprotein highly expressed on myeloma cells, inducing cell death through multiple immune-mediated mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription, while dexamethasone is a corticosteroid that provides anti-inflammatory and immunosuppressive effects while enhancing the efficacy of other myeloma therapies. The regimen was evaluated in a Phase II trial (NCT02951819) by the Canadian Myeloma Research Group (CMRG) as a backbone for RRMM treatment.
- Other names
- D-CyDexDara-Cy-Dex
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)DNA
Beyond the preview
Go deeper on daratumumab + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + cyclophosphamide + dexamethasone.